5-Fluoro-AET, also known as 5-fluoro-α-ethyltryptamine or by the code name PAL-545, is a substituted tryptamine derivative which acts as a serotonin–dopamine releasing agent (SDRA) and as an agonist of the serotonin 5-HT2A receptor.[1]

Its EC50Tooltip half-maximal effective concentration values for monoamine release are 36.6 nM for serotonin, 5,334 nM for norepinephrine, and 150 nM for dopamine in rat brain synaptosomes.[1] Its EC50 at the serotonin 5-HT2A receptor is 246 nM and its EmaxTooltip maximal efficacy at the receptor is 87%.[1]

Several close analogues of 5-fluoro-αET, including 5-fluoro-αMT and 5-chloro-αMT, are known to be potent monoamine oxidase inhibitors (MAOIs), specifically of monoamine oxidase A (MAO-A).[2] However, α-ethyltryptamine (αET) is a very weak MAOI.[3][4] 5-Fluoro-αET has also more recently been assessed, and in contrast to αET, but similarly to drugs like 5-fluoro-αET, was found to be a potent MAOI, with an IC50Tooltip half-maximal inhibitory concentration of 2,480 nM.[5] Potent monoamine oxidase inhibition by monoamine releasing agents (MRAs) has been associated with dangerous and sometimes fatal toxicity in humans.[2]

See also

References

  1. ^ a b c Blough BE, Landavazo A, Partilla JS, Decker AM, Page KM, Baumann MH, Rothman RB (October 2014). "Alpha-ethyltryptamines as dual dopamine-serotonin releasers". Bioorganic & Medicinal Chemistry Letters. 24 (19): 4754–4758. doi:10.1016/j.bmcl.2014.07.062. PMC 4211607. PMID 25193229.
  2. ^ a b Reyes-Parada M, Iturriaga-Vasquez P, Cassels BK (2019). "Amphetamine Derivatives as Monoamine Oxidase Inhibitors". Front Pharmacol. 10: 1590. doi:10.3389/fphar.2019.01590. PMC 6989591. PMID 32038257. Several close analogues of 5-chloro-αET, such as 5-chloro-αMT and 5-fluoro-αMT, are known to be potent monoamine oxidase inhibitors (MAOIs).
  3. ^ Glennon RA, Dukat MG (December 2023). "α-Ethyltryptamine: A Ratiocinatory Review of a Forgotten Antidepressant". ACS Pharmacology & Translational Science. 6 (12): 1780–1789. doi:10.1021/acsptsci.3c00139. PMC 10714429. PMID 38093842.
  4. ^ Ask AL, Fagervall I, Ross SB (September 1983). "Selective inhibition of monoamine oxidase in monoaminergic neurons in the rat brain". Naunyn-Schmiedeberg's Archives of Pharmacology. 324 (2): 79–87. doi:10.1007/BF00497011. PMID 6646243.
  5. ^ "Advantageous tryptamine compositions for mental disorders or enhancement". Google Patents. 20 September 2021. Retrieved 11 November 2024.


No tags for this post.